BioCentury | Jan 12, 2015
Clinical News

Carmeseal-MD regulatory update

...Phrixus and Ethicor Pharma Ltd. (London, U.K.) will begin a European access program this month to provide Carmeseal-MD...
BioCentury | Aug 11, 2014
Clinical News

Lasofoxifene: Phase I data

...commercialize a new formulation of lasofoxifene for an undisclosed women’s health indication. Ligand also granted Ethicor Pharma Ltd....
BioCentury | Nov 25, 2013
Company News

Ethicor Pharma, RXi Pharmaceuticals sales and marketing update

...out subsidiary RXi to develop RXI-109 (see BioCentury, April 30, 2012 & Oct. 1, 2012). Ethicor Pharma Ltd....
BioCentury | Jul 29, 2013
Company News

Azure Biotech Inc., Ethicor Pharma, Ligand deal

...Ligand from Pfizer (see BioCentury, Jan. 19, 2009). Azure Biotech Inc. , New York, N.Y. Ethicor Pharma Ltd....
Items per page:
1 - 4 of 4
BioCentury | Jan 12, 2015
Clinical News

Carmeseal-MD regulatory update

...Phrixus and Ethicor Pharma Ltd. (London, U.K.) will begin a European access program this month to provide Carmeseal-MD...
BioCentury | Aug 11, 2014
Clinical News

Lasofoxifene: Phase I data

...commercialize a new formulation of lasofoxifene for an undisclosed women’s health indication. Ligand also granted Ethicor Pharma Ltd....
BioCentury | Nov 25, 2013
Company News

Ethicor Pharma, RXi Pharmaceuticals sales and marketing update

...out subsidiary RXi to develop RXI-109 (see BioCentury, April 30, 2012 & Oct. 1, 2012). Ethicor Pharma Ltd....
BioCentury | Jul 29, 2013
Company News

Azure Biotech Inc., Ethicor Pharma, Ligand deal

...Ligand from Pfizer (see BioCentury, Jan. 19, 2009). Azure Biotech Inc. , New York, N.Y. Ethicor Pharma Ltd....
Items per page:
1 - 4 of 4